Barring an appeals court reversal, Amgen Inc. may be able to keep biosimilars to its top-selling drug Enbrel (etancercept) off the market for another decade now that a district court has upheld the validity of patents covering the compound's active ingredient and method of manufacture.
Three years after Sandoz Inc. obtained FDA approval of its biosimilar Erelzi (etanercept-szzs), the US District Court for the...






